NORWOOD,
Mass., Oct. 14, 2022 /PRNewswire/ -- Corbus
Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the
"Company"), an immunology company, today announced a poster
presentation at the SITC 2022 Annual Meeting being held
November 8-12, 2022. The poster will
share the updated preclinical validation of the drug candidate
CRB-601.
Poster Details:
Title: CRB-601, a selective integrin avβ8 blocking
antibody, exhibits potent anti-tumor activity in anti-PD-1
resistant models
Authors: Daqing Wang, Vaishali Shinde, Maneesh
Singh, Rachael Brake, and
Andrew Kolodziej
Abstract Number: 815
Date / Time: November 10 – November 11, 9:00 am -
9:00 pm ET
CRB-601 is a potent and selective integrin αvβ8 blocking
monoclonal antibody that can overcome tumor immune exclusion and
enhance the activity of immune checkpoint inhibitors in
vivo. Investigational New Drug (IND) enabling studies are
currently underway with a plan to explore the anti-tumor activity
of this agent clinically in 2023.
The CRB-601 abstract will be available on the SITC website as of
November 7th and the
poster will be made available on the Company website on
November 10th.
About Corbus
Corbus is an immunology company committed to helping people
defeat serious illness by bringing innovative scientific approaches
to well understood biological pathways. Corbus' current pipeline
includes anti-integrin monoclonal antibodies that block activation
of TGFβ and small molecules that activate or inhibit the
endocannabinoid system. Corbus is headquartered in Norwood, Massachusetts. For more information
on Corbus, visit corbuspharma.com. Connect with us on Twitter,
LinkedIn and Facebook.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934 and Private
Securities Litigation Reform Act, as amended, including those
relating to the Company's restructuring, trial results, product
development, clinical and regulatory timelines, market opportunity,
competitive position, possible or assumed future results of
operations, business strategies, potential growth opportunities and
other statement that are predictive in nature. These
forward-looking statements are based on current expectations,
estimates, forecasts and projections about the industry and markets
in which we operate and management's current beliefs and
assumptions.
These statements may be identified by the use of forward-looking
expressions, including, but not limited to, "expect," "anticipate,"
"intend," "plan," "believe," "estimate," "potential," "predict,"
"project," "should," "would" and similar expressions and the
negatives of those terms. These statements relate to future events
or our financial performance and involve known and unknown risks,
uncertainties, and other factors, including the potential impact of
the recent COVID-19 pandemic and the potential impact of sustained
social distancing efforts, on our operations, clinical development
plans and timelines, which may cause actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Such factors include those set forth in
the Company's filings with the Securities and Exchange Commission.
Prospective investors are cautioned not to place undue reliance on
such forward-looking statements, which speak only as of the date of
this press release. The Company undertakes no obligation to
publicly update any forward-looking statement, whether as a result
of new information, future events or otherwise.
INVESTOR CONTACT:
Sean Moran
smoran@corbuspharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/corbus-pharmaceuticals-to-present-pre-clinical-data-for-crb-601-at-the-society-for-immunotherapy-of-cancer-sitc-37th-annual-meeting-301649256.html
SOURCE Corbus Pharmaceuticals